Khateb, A.* ; Deshpande, A.* ; Feng, Y.* ; Finlay, D.* ; Lee, J.S.* ; Lazar, I.* ; Fabre, B.* ; Li, Y.* ; Fujita, Y.* ; Zhang, T.* ; Yin, J.* ; Pass, I.* ; Livneh, I.* ; Jeremias, I. ; Burian, C.* ; Mason, J.R.* ; Almog, R.* ; Horesh, N.* ; Ofran, Y.* ; Brown, K.* ; Vuori, K.* ; Jackson, M.* ; Ruppin, E.* ; Deshpande, A.J.* ; Ronai, Z.A.*
The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors.
Nat. Commun. 12:5397 (2021)
Acute myeloid leukemia (AML) remains incurable, largely due to its resistance to conventional treatments. Here, we find that increased abundance of the ubiquitin ligase RNF5 contributes to AML development and survival. High RNF5 expression in AML patient specimens correlates with poor prognosis. RNF5 inhibition decreases AML cell growth in culture, in patient-derived xenograft (PDX) samples and in vivo, and delays development of MLL-AF9–driven leukemogenesis in mice, prolonging their survival. RNF5 inhibition causes transcriptional changes that overlap with those seen upon histone deacetylase (HDAC)1 inhibition. RNF5 induces the formation of K29 ubiquitin chains on the histone-binding protein RBBP4, promoting its recruitment to and subsequent epigenetic regulation of genes involved in AML maintenance. Correspondingly, RNF5 or RBBP4 knockdown enhances AML cell sensitivity to HDAC inhibitors. Notably, low expression of both RNF5 and HDAC coincides with a favorable prognosis. Our studies identify an ERAD-independent role for RNF5, demonstrating that its control of RBBP4 constitutes an epigenetic pathway that drives AML, and highlight RNF5/RBBP4 as markers useful to stratify patients for treatment with HDAC inhibitors.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Reticulum-associated Degradation; Apoptosis; Binding; Identification; Expression; Prognosis; Proteins; Phase-1; Complex; Cells
Keywords plus
Language
english
Publication Year
2021
Prepublished in Year
HGF-reported in Year
2021
ISSN (print) / ISBN
2041-1723
e-ISSN
2041-1723
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 12,
Issue: 1,
Pages: ,
Article Number: 5397
Supplement: ,
Series
Publisher
Nature Publishing Group
Publishing Place
London
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
Institute(s)
Research Unit Apoptosis in Hematopoietic Stem Cells (AHS)
POF-Topic(s)
30204 - Cell Programming and Repair
Research field(s)
Stem Cell and Neuroscience
PSP Element(s)
G-506600-001
Grants
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
Copyright
Erfassungsdatum
2021-10-15